Companion diagnostics

Digital pathology and tissue image analysis tools are essential to developing companion diagnostics and enabling pathologists to support clinical decisions, but there is still work to be done…

What does analysis of the last five years of literature on companion diagnostics tell us about the priorities of the field, and the contributors to it?

Keith Miller is Director and co-founder of CADQAS (Cancer Diagnostic Quality Assurance Services), a not-for-profit community interest company hosted by Poundbury Cancer Institute (PCI).

Christopher Hudson is Director of Tissue Diagnostics UK and Ireland at Roche, the multinational life sciences company that supports the Poundbury Cancer Institute through funding and research collaboration.

Poundbury Cancer Institute aims to put pathology at the forefront of cancer research, and bring industry, national healthcare service and quality assurance together to expand the use of companion diagnostics and important biological markers.

At the Poundbury Cancer Center, pathology, business and quality assurance are uniting to create a cutting-edge home for companion diagnostics.

To fail to change is to fail patients

Han van Krieken discusses the ways in which laboratory medicine is evolving, the difference between old and young pathologists, and the obstacles facing both of them today

Metabolic bone disease is highly prevalent, and although bone turnover marker (BTM) assays have a key role to play in its diagnosis and monitoring, the lack of internationally recognized guidelines for the interpretation of patient results has limited their clinical usefulness.